文献速递心脑血管急症重症综合管理与镇静镇痛

氨甲环酸对巴西蛛网膜下腔出血患者的影响:一项倾向性评分分析的前瞻性观察研究

Effects of Tranexamic Acid in Patients with Subarachnoid Hemorrhage in Brazil: A Prospective Observational Study with Propensity Score Analysis.
PubMed 文献 · Neurocrit Care · 2023-05-02
一句话结论在动脉瘤未早期处理的aSAH患者中,氨甲环酸未改善6个月功能结局,且住院死亡率更高(33% vs 11%,OR 4.13)。

该单中心前瞻性观察研究纳入2016年12月至2020年2月巴西一家高容量三级医院的230例aSAH患者,比较接受与未接受氨甲环酸(TXA)者的长期功能结局。采用倾向性评分逆概率治疗加权多因素logistic回归,TXA组与非TXA组6个月不良结局(mRS 4-6)率无显著差异(48% vs 33%;OR 1.39,95%CI 0.67-2.92;p=0.377)。TXA组住院死亡率更高(33% vs 11%;OR 4.13,95%CI 1.55-12.53;p=0.007)。再出血率和迟发性脑缺血率两组无差异。倾向性匹配分析(各64例)同样显示6个月不良结局率无差异(45% vs 36%;OR 1.22,95%CI 0.51-2.89;p=0.655)。作者认为在动脉瘤处理延迟的队列中,动脉瘤闭塞前使用TXA不改善功能结局。

要点

  • 在动脉瘤处理延迟的aSAH队列中,TXA组与非TXA组6个月不良结局(mRS 4-6)率无显著差异:48% vs 33%,OR 1.39(95%CI 0.67-2.92),p=0.377。
  • TXA组住院死亡率显著高于非TXA组:33% vs 11%,OR 4.13(95%CI 1.55-12.53),p=0.007。
  • 倾向性匹配分析(各64例)中6个月不良结局率仍无差异:TXA组45% vs 非TXA组36%,OR 1.22(95%CI 0.51-2.89),p=0.655。
  • 再出血率(TXA组7.8% vs 非TXA组8.9%,p=0.31)和迟发性脑缺血率(TXA组27% vs 非TXA组19%,p=0.14)两组无差异。
  • ICU住院时长(TXA组16±11.22天 vs 非TXA组14±9.24天,p=0.2)和总住院时长(TXA组23±13.35天 vs 非TXA组22±13.36天,p=0.9)两组无差异。

适用人群与场景

  • 纳入2016年12月至2020年2月巴西一家高容量三级医院连续收治的230例动脉瘤性蛛网膜下腔出血(aSAH)患者,均接受或未接受氨甲环酸治疗。
  • 中位年龄55(IQR 46-63)岁,女性占72%,75%为良好临床分级(WFNS 1-3级),83% Fisher分级为3或4级,约80%在发病72小时内入院。
  • 动脉瘤闭塞方式为手术夹闭者占80%。

研究设计与关键结果

  • 研究类型:单中心前瞻性观察研究,采用倾向性评分逆概率治疗加权多因素logistic回归分析,共纳入230例aSAH患者,129例(56%)接受TXA。
  • 主要终点:6个月不良功能结局(mRS 4-6)率在TXA组与非TXA组无显著差异(61例[48%] vs 33例[33%];OR 1.39,95%CI 0.67-2.92;p=0.377)。
  • 关键次要终点:TXA组住院死亡率高于非TXA组(33% vs 11%;OR 4.13,95%CI 1.55-12.53;p=0.007)。
  • 其他终点:ICU住院时长TXA组16±11.22天 vs 非TXA组14±9.24天(p=0.2);总住院时长TXA组23±13.35天 vs 非TXA组22±13.36天(p=0.9);再出血率TXA组7.8% vs 非TXA组8.9%(p=0.31);迟发性脑缺血率TXA组27% vs 非TXA组19%(p=0.14)。
  • 倾向性匹配分析:选取128例(TXA组64例,非TXA组64例),6个月不良结局率TXA组45% vs 非TXA组36%(OR 1.22,95%CI 0.51-2.89;p=0.655)。

证据类型、等级与局限

  • 证据类型:单中心前瞻性观察研究,采用倾向性评分分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在动脉瘤处理延迟的队列中,动脉瘤闭塞前使用TXA不改善aSAH患者的功能结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Rebleeding from a ruptured aneurysm increases the risk of unfavorable outcomes after subarachnoid hemorrhage (SAH) and is prevented by early aneurysm occlusion. The role of antifibrinolytics before aneurysm obliteration remains controversial. We investigated the effects of tranexamic acid on long-term functional outcomes of patients with aneurysmal SAH (aSAH).

METHODS: This was a single-center, prospective, observational study conducted in a high-volume tertiary hospital in a middle-income country from December 2016 to February 2020. We included all consecutive patients with aSAH who either received or did not receive tranexamic acid (TXA) treatment. Multivariate logistic regression analysis using propensity score was used to evaluate the association of TXA use with long-term functional outcomes, measured by the modified Rankin Scale (mRS) at 6 months.

RESULTS: A total of 230 patients with aSAH were analyzed. The median (interquartile range) age was 55 (46-63) years, 72% were women, 75% presented with good clinical grade (World Federation of Neurological Surgeons grade 1-3), and 83% had a Fisher scale of 3 or 4. Around 80% of patients were admitted up to 72 h from ictus. The aneurysm occlusion method was surgical clipping in 80% of the patients. A total of 129 patients (56%) received TXA. In multivariable logistic regression using inverse probability treatment weighting, the long-term rate of unfavorable outcomes (modified Rankin scale 4-6) was the same in the TXA and non-TXA groups (61 [48%] in TXA group vs. 33 [33%] in non-TXA group; odds ratio [OR] 1.39, 95% confidence interval [CI] 0.67-2.92; p = 0.377). The TXA group had higher in-hospital mortality (33 vs. 11% in non-TXA group; OR 4.13, 95% CI 1.55-12.53, p = 0.007). There were no differences between the groups concerning intensive care unit length of stay (16 ± 11.22 days in TXA group vs. 14 ± 9.24 days in non-TXA group; p = 0.2) or hospital (23 ± 13.35 days in TXA group vs. 22 ± 13.36 days in non-TXA group; p = 0.9). There was no difference in the rates of rebleeding (7.8% in TXA group vs. 8.9% in non-TXA group; p = 0.31) or delayed cerebral ischemia (27% in TXA group vs. 19% in non-TXA group; p = 0.14). For the propensity-matched analysis, 128 individuals were selected (64 in TXA group and 64 in non-TXA group), and the rates of unfavorable outcomes at 6 months were also similar between groups (45% in TXA group and 36% in non-TXA group; OR 1.22, 95% CI 0.51-2.89; p = 0.655).

CONCLUSIONS: Our findings in a cohort with delayed aneurysm treatment reinforce previous data that TXA use before aneurysm occlusion does not improve functional outcomes in aSAH.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Rynkowski CB, Hegele V, Soares PHR, et al. Effects of Tranexamic Acid in Patients with Subarachnoid Hemorrhage in Brazil: A Prospective Observational Study with Propensity Score Analysis. Neurocrit Care. 2023. PMID: 37131089. doi:10.1007/s12028-023-01732-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。